Lanreotide Zentiva

Lanreotide, the active ingredient in Lanreotide Zentiva, is a somatostatin analog presented as an unknown/unknown for subcutaneous use. It treats acromegaly and neuroendocrine tumors in adult patients. GNH USA supplies Lanreotide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lanreotide Zentiva is a somatostatin analog used in endocrine disorders that involve excess hormone secretion. - Acromegaly: reduces growth hormone levels and controls disease activity. - Neuroendocrine tumors: inhibits secretion of vasoactive peptides and slows tumor‑related symptom progression.

Adverse reactions may occur with Lanreotide administration.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Gastrointestinal disturbances: diarrhea, abdominal pain, nausea. - Headache: transient mild to moderate headache. - Hyperglycemia: elevated blood glucose, especially in diabetic patients.

Serious or Rare Side Effects: - Gallbladder disease: formation of gallstones or cholecystitis. - Pancreatitis: inflammation of the pancreas requiring medical attention. - Severe allergic reactions: anaphylaxis, angioedema, or severe rash. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Before initiating therapy, clinicians should consider several safety aspects. - Monitor glucose levels: patients with diabetes may experience worsening hyperglycemia. - Assess gallbladder status: risk of gallstone formation warrants periodic imaging. - Evaluate cardiac function: observe for bradycardia or arrhythmias. - Avoid use in known hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with other medicines, requiring vigilance.

Major Interactions (Avoid): - Insulin and oral hypoglycemics: may potentiate hypoglycemia, dose adjustments needed. - Cyclosporine: increased cyclosporine concentrations have been reported. - Concurrent somatostatin analogs: additive hormonal suppression, avoid co‑administration.

Moderate Interactions (Monitor Closely): - SSRIs and other antidepressants: may enhance gastrointestinal side effects. - Warfarin: monitor INR for potential anticoagulation changes. - Diuretics: watch electrolyte balance, especially potassium.